Low sodium cotransport in red cells with physiological internal sodium concentration in essential hypertension.
Ouabain-resistant Na and Li effluxes in erythrocytes from 18 normal subjects and 19 hypertensive subjects were studied in fresh cells that contained about 9 mmol Li and 2.5 or 6.5 mmol Na per liter of erythrocytes after intact cells had been incubated for 5 hours in 110 mM Li, 40 mM Na medium, with or without ouabain 10(-4) M. Outward Na cotransport was estimated at both internal Na concentrations as the furosemide-sensitive unidirectional 22Na efflux from erythrocytes into a Na free-medium containing 75 mM MgCl2. The changes in furosemide-sensitive outward Na transport between the two levels of internal Na were considered as a measure of the response of Na cotransport to the changes in internal Na within its physiological range. At both levels of internal Na, outward Na cotransport was reduced in the majority but not in all of the patients with essential hypertension (p less than 0.05 at 2.5 mmol; p less than 0.001 at 6.5 mmol). The ratio of the changes in Na cotransport to those in internal Na was lower in the hypertensive patients than in the control subjects (17.2 mumol/liter red blood cells/hr/1 mmol in internal Na increase vs 42.2, p less than 0.001). The Li-Na countertransport was increased in a few patients with essential hypertension, with no relationship to cotransport. We conclude that, in essential hypertension, the outward Na + K cotransport is impaired in fresh erythrocytes not treated with PCMBS (2,5 p-chloromercuribenzene sulfonate) or nystatin, even when internal Na is around its physiological range.
D002731:4-Chloromercuribenzenesulfonate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D001692:Biological Transport / Q000187:drug effects; D001794:Blood Pressure; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000378:metabolism; D008094:Lithium / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000097:blood / Q000378:metabolism*; D012964:Sodium / Q000097:blood / Q000378:metabolism*
D009761:Nystatin; D010042:Ouabain; D002731:4-Chloromercuribenzenesulfonate; D005665:Furosemide; D008094:Lithium; D012964:Sodium; D011188:Potassium